Information Provided By: 
Fly News Breaks for January 2, 2019
INSM
Jan 2, 2019 | 07:29 EDT
Canaccord analyst Dewey Steadman initiated Insmed with a Buy rating as he views the launch of Arikayce positively given the severe unmet need in nontuberculous mycobacterial lung disease and the potential for the drug to become core to the NTM treatment paradigm over time. He believes Insmend is well positioned as a specialty play and thinks the company has been unfairly caught up in broader infectious disease market meltdown as several antibiotic companies have disappointed investors. Steadman has a $20 price target on Insmed shares.
News For INSM From the Last 2 Days
There are no results for your query INSM
